Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Papillomavirus Infections 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 40Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 32Papillomavirus Vaccines 24Human Papillomavirus Recombinant Vaccine nonavalent 12Vaccines 11Blood Specimen Collection 10Data Collection 9Colposcopy 9Human Papillomavirus DNA Tests 8Specimen Handling 7Radiotherapy, Intensity-Modulated 7Cisplatin 7Surveys and Questionnaires 6Educational Status 6Early Intervention, Educational 6Carboplatin 6Vaginal Smears 5Vaccines, Synthetic 5Methods 5Engerix-B 4fludarabine 3epigallocatechin gallate 3artesunic acid 3artemisinin 3Watchful Waiting 3Polymerase Chain Reaction 3Patient Navigation 3Paclitaxel 3Observation 3Mass Screening 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Papillomavirus Infections × Chorionic Villi Sampling × Clear all
NCT00947115 2020-10-30

Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects

GlaxoSmithKline

Phase 3 Completed
525 enrolled 24 charts
Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡